Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary obtaining a medical device registration certificate issued by a regulatory authority (Zhejiang Provincial Drug Administration). It describes the product details, registration certificate specifics, and potential impact on company performance. The document is short (1149 characters), primarily informative about a regulatory approval event, and does not contain financial statements, earnings data, or detailed management discussion. It is not an annual or interim report, earnings release, or management report. It is also not a regulatory filing about compliance or officer certification. The content fits best as a general regulatory announcement about a material event affecting the company, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2024-01-16 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding percentage of an individual shareholder, 陈朝红, due to dilution from a stock incentive plan. The document includes sections on the purpose of the equity change, the method of change, and confirms no actual change in share quantity but a dilution in percentage below 5%. It also references compliance with Chinese securities laws and disclosure requirements. This type of document is a notification of a change in major shareholding levels, specifically a shareholding falling below the 5% threshold due to dilution. It is not a full financial report, earnings release, or management report. It is not an announcement of a report publication but the report itself. Therefore, the correct classification is Major Shareholding Notification (MRQ). The document length (6381 characters) supports it being a full report rather than a brief announcement or certification.
2024-01-16 Chinese
关于全资子公司通过国家高新技术企业重新认定的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the re-certification of its wholly-owned subsidiary as a national high-tech enterprise by relevant government authorities. It includes details about the certificate issuance, tax benefits, and the impact on the company. There are no financial statements, earnings data, or detailed management analysis. The document is relatively short (826 characters) and serves as a regulatory announcement about a non-financial corporate event. It does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-01-12 Chinese
关于2023年限制性股票激励计划第一类限制性股票授予登记完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from 美康生物科技股份有限公司 regarding the completion of the registration of the first class of restricted stock under the 2023 restricted stock incentive plan. It details the number of shares granted, the grant price, the recipients, approval procedures, stock source, listing date, and the impact on shareholding structure and control. It also includes information about the verification of subscription funds by an accounting firm and the use of raised funds. The document is a formal disclosure about a stock incentive plan and its registration completion, which relates to share issuance and capital changes. It is not a full financial report, earnings release, or management discussion, nor is it a voting result or board change announcement. The content fits best under the category of Share Issue/Capital Change (SHA) because it announces the issuance and registration of new restricted shares as part of an incentive plan, affecting the company's capital structure.
2024-01-12 Chinese
关于诉讼事项执行情况的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the execution status of litigation matters. It details the background of the lawsuits, court mediation results, changes in shareholding due to litigation settlement, receipt of payment related to the case, and the impact on the company's profits. It also states that there are no other undisclosed significant litigation or arbitration matters. The document includes references to court mediation documents and payment receipts but does not contain financial statements or detailed financial analysis. The length is 2181 characters, which is relatively short and the content is focused on legal proceedings and their execution status rather than a full audit or annual report. Therefore, this document fits best under Legal Proceedings Report (LTR) as it provides updates on significant lawsuits and legal matters involving the company.
2024-01-09 Chinese
关于通过国家高新技术企业重新认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving a renewed National High-Tech Enterprise Certificate. It includes no financial statements, no detailed financial data, no management discussion, no voting results, no regulatory certifications, or other report content. The document is only informing about a certificate issuance and related tax benefits, with a statement to investors about risk. The length is only 592 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial data. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-01-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.